Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply

Mickaël Hiligsmann, Benedict G Dellaert, Verity Watson, Annelies Boonen

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].
Original languageEnglish
Pages (from-to)584-585
Number of pages2
JournalRheumatology
Volume57
Issue number3
Early online date28 Nov 2017
DOIs
Publication statusPublished - 30 Mar 2018

Fingerprint

Patient Preference
Osteoporosis
Pharmaceutical Preparations

Keywords

  • Journal Article

Cite this

Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply. / Hiligsmann, Mickaël; Dellaert, Benedict G; Watson, Verity; Boonen, Annelies.

In: Rheumatology, Vol. 57, No. 3, 30.03.2018, p. 584-585.

Research output: Contribution to journalComment/debate

Hiligsmann, Mickaël ; Dellaert, Benedict G ; Watson, Verity ; Boonen, Annelies. / Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply. In: Rheumatology. 2018 ; Vol. 57, No. 3. pp. 584-585.
@article{270e2c2832384791bdc14d8276d2aeaf,
title = "Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply",
abstract = "We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].",
keywords = "Journal Article",
author = "Micka{\"e}l Hiligsmann and Dellaert, {Benedict G} and Verity Watson and Annelies Boonen",
note = "Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.",
year = "2018",
month = "3",
day = "30",
doi = "10.1093/rheumatology/kex430",
language = "English",
volume = "57",
pages = "584--585",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "OXFORD UNIV PRESS INC",
number = "3",

}

TY - JOUR

T1 - Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply

AU - Hiligsmann, Mickaël

AU - Dellaert, Benedict G

AU - Watson, Verity

AU - Boonen, Annelies

N1 - Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

PY - 2018/3/30

Y1 - 2018/3/30

N2 - We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].

AB - We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].

KW - Journal Article

U2 - 10.1093/rheumatology/kex430

DO - 10.1093/rheumatology/kex430

M3 - Comment/debate

VL - 57

SP - 584

EP - 585

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 3

ER -